What You Should Know:
- PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development.
- This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
ATOMIC-Meso Trial: A New Take Against Pleural Mesothelioma
Pleural mesothelioma is a type of an aggressive cancer that develops in the tissue that surrounds the lung cavity. It is known to be primarily caused by asbestos exposure. Asbestos was largely used as a material in products revolving construction, automobile, and insulation. It is apparently still used in the said products today in buildings and houses in the U.S. The clear disparity between its latency period, which generally takes decades, compared to its fatal ramifications and little chance
Read More
Lindus Health Raises $55M to Accelerate AI-Driven Clinical Trials
What You Should Know:
- Lindus Health, a company transforming the clinical trial landscape with its tech-first approach raises $55M in Series B funding round led by Balderton Capital, with participation from Visionaries Club and existing investors Creandum, Firstminute, and Seedcamp.
- The funding will fuel the continued development of Lindus Health's AI technology and eClinical platform, Citrus™, and support the company's mission to make clinical trials faster, more reliable,
Read More
Beyond Chatbots: How AI is Reshaping Medical Information Delivery
The demand for accurate and timely medical information has never been greater. As healthcare providers and patients navigate an increasingly complex landscape of therapies and treatments, the need for accessible and reliable MI is critical to delivering quality care. Organizations are moving away from traditional call centers and embracing artificial intelligence-enhanced digital solutions to meet these growing demands. This shift addresses the rising volume and complexity of inquiries and
Read More
SandboxAQ and Google Cloud Partner to Optimize Large Quantitative Models
What You Should Know:
- SandboxAQ, a leader in artificial intelligence (AI) solutions, today announced a strategic partnership with Google Cloud to integrate and optimize its platform of Large Quantitative Models (LQMs) on Google Cloud.
- The collaboration will leverage Google Cloud's robust infrastructure and advanced capabilities to enhance the performance and scalability of SandboxAQ's AI solutions while making them more accessible to customers through Google Cloud
Read More
Guardant Health and ConcertAI Partner to Unlock Cancer Insights with Multi-Modal Real-World Data
What You Should Know:
- Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.
- The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper
Read More
TetraScience & Microsoft Partner to Advance Scientific AI in Biopharma
What You Should Know:
- TetraScience, a provider of scientific data cloud solutions announced a strategic collaboration with Microsoft to accelerate the adoption of artificial intelligence (AI) in the biopharmaceutical industry.
- The strategic partnership combines TetraScience's Scientific Data and AI Cloud with the power and security of Microsoft Azure, creating a robust platform for scientific organizations to extract valuable insights from their complex experimental
Read More
Is AI Failing Drug Development? The Unseen Challenges
For over a decade, we've heard about AI's transformative potential in therapeutics (Tx), but where's the evidence? Has it all been hype? Can AI still revolutionize Tx? Or is there something the AI experts aren't telling us?
First, some facts. The process of Tx development—from early clinical trials to FDA approval—is excruciatingly slow (over 10 years), expensive (over $2B, especially for immunotherapy drugs), and comes with a low probability of success (5% in Immune-Oncology, and similarly
Read More
Increasing Participation in Muscular Dystrophy Clinical Trials
Muscular Dystrophy (MD) refers to a group of rare genetic conditions that cause progressive muscle weakness and degeneration in patients. Some forms of MD, such as Duchenne Muscular Dystrophy (DMD), can be life threatening to heart and respiratory functions.
But recent research found that among 3,661 U.S. patients with Muscular Dystrophy, only 33% of those with Duchenne and 12% of those with Becker Muscular Dystrophy - a similar but milder and later-onset MD condition - have previously
Read More
Lantheus (LNTH) Acquires Life Molecular Imaging for $750M
What You Should Know:
- Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350M upfront and up to an additional $400M in potential earn-out and milestone payments.
- The strategic acquisition strengthens Lantheus' position in the radiopharmaceutical market and establishes a commercial presence in the Alzheimer's disease (AD) space.
Life Molecular Imaging
Read More
